



**UNITED STATES  
NUCLEAR REGULATORY COMMISSION**

REGION IV  
1600 E. LAMAR BLVD  
ARLINGTON, TX 76011-4511

April 15, 2021

PharmaLogic Holdings Corp.  
433 Plaza Real  
Suite 275  
Boca Raton, FL 33432  
(via email: [kmadagan@reedsmith.com](mailto:kmadagan@reedsmith.com))

SUBJECT: NOTICE OF TRANSACTION

The Nuclear Regulatory Commission (NRC) has received a notification letter dated March 22, 2021 from PharmaLogic Holdings Corporation describing a business transaction impacting radioactive materials licenses issued by NRC Region IV to Pharmalogic MT, Inc., and Pharmalogic WY, Inc. Staff from the NRC Region IV office reviewed the business transaction against the licensing guidance in NUREG-1556, Volume 15, revision 1, "Consolidated Guidance About Materials Licenses, Guidance About Changes of Control and About Bankruptcy Involving Byproduct, Source of Special Nuclear Materials Licenses," and determined that the business transaction is not a change of control of licensed activities involving NRC Region IV licenses.

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at [www.nrc.gov/reading-rm/adams.html](http://www.nrc.gov/reading-rm/adams.html).

Thank you for your cooperation.

Sincerely,

Roberto J. Torres, M.S., Senior Health Physicist  
Materials Licensing and Decommissioning Branch

Dockets: 030-38401, 030-38007  
Licenses: 09-29398-01MD, 49-27629-01MD  
Controls: 625394, 625395